We want to remind all our members, followers and friends that session proposal submissions for the ESTIV 2026 Congress in Maastricht (June 29- July 2, 2026) are now open!
This is your opportunity to contribute to the program of a landmark event in in vitro toxicology, in silico approaches and regulatory science. We are especially eager to include sessions that:
🔬 Share and advance the knowledge of novel in vitro methods, MPS and testing strategies used in R&D and preclinical research
đź’» Showcase innovations in QSARs, Artifical Intelligence and Machine Learning use
📜 Discuss new frontiers in regulatory toxicology and their societal impact, need for education and training in in 3Rs
🧬 Explore the potential of AOPs (Adverse Outcome Pathways) in risk assessment
📅 Deadline for submission: Tuesday April 1, 2025 ⏰11:59am (CEST).
đź’» Submit now: https://lnkd.in/dmj2g_Gg
Let’s work together to make ESTIV2026 a platform for groundbreaking science, fostering collaborations that bridge academia, industry, regulators and NGOs. Don’t miss this opportunity to leave your mark on the scientific and regulatory landscape. Submit your session proposal today!
Related content
Special Issue completed – ESTIV 2024: The Application of New Approach Methodologies (NAMs) in Drug Discovery and Drug and Chemical Safety Assessment
ESTIV would like to extend its heartfelt thanks to all contributors to this special issue, which highlights some of the science and activities that took place during the congress.
ESTIV 2026 LAST-MINUTE ABSTRACT SUBMISSION OPEN
We are pleased to announce that last‑minute poster abstract submissions are now open.
Researchers who still wish to contribute are warmly invited to submit their work. The deadline for last‑minute submissions is 8 May 2026 at 23:59 CET.
ESTIV-ASCCT:Â Award Winners Series: AI & Machine Learning
Check out the details on the next installment of our ESTIV – ASCCT Award Winners Webinar and make sure to register if you haven’t already. We hope to see you there!
The ESTIV Members Area




















